TCLF 2017

 
 
 

 

Drug produces high response rates in AITL

Jen Smith Read Article
Published: 02/07/17

DeLarue-Richard-TCLF2017-230.jpg
Richard Delarue, MD
Photo by Larry Young

Treatment with 5-azacitidine (5-AZA) can produce a high response rate in patients with relapsed/refractory angioimmunoblastic T-cell lymphoma (AITL), according to a small study. The overall response rate (ORR) among AITL patients was 75%, and the complete response (CR) rate was 42%. However, this study also included patients with other types of peripheral T-cell lymphoma (PTCL), and most of these patients did not respond to 5-AZA. [Read Article]

OS is worse with refractory vs relapsed PTCL

Jen Smith Read Article
Published: 02/03/17

Lansigan-Fredrick-TCLF2017-230.jpg
Frederick Lansigan, MD
Photo by Larry Young

Patients with refractory peripheral T-cell lymphoma (PTCL) have significantly worse overall survival (OS) than patients with relapsed PTCL, according to data from the COMPLETE registry. The data also showed that patients treated with a curative intent had significantly better OS than patients who received palliative care. However, there was no significant difference in OS according to disease subtype or between patients who received conventional . . . [Read Article]

Regimens seem similarly effective in ENKTL

Jen Smith Read Article
Published: 02/02/17

Huang-Huiqiang-TCLF2017-230.jpg
Huiqiang Huang, MD
Photo by Larry Young

Interim results of a phase 3 trial suggest 2 treatment regimens may provide comparable efficacy in patients with extranodal natural killer/T-cell lymphoma (ENKTL), though 1 regimen appears more toxic than the other. In this ongoing trial, investigators are comparing pegaspargase, gemcitabine, oxaliplatin, and thalidomide (P-Gemox+Thal) to pegaspargase, methotrexate, calcium folinate, and dexamethasone (AspaMetDex). [Read Article]

Group proposes new prognostic model for PTCL-NOS

Jen Smith Read Article
Published: 02/01/17

TCLF-2017-session-210.jpg
Session at the 9th Annual
T-cell Lymphoma Forum
Photo by Larry Young

Researchers have used data from the T-Cell Project (TCP) to create a prognostic model for peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). Analyses have suggested the TCP model is more accurate for PTCL-NOS than 4 other prognostic models—the International Prognostic Index (IPI), the Prognostic Index for T-cell Lymphoma (PIT), the International Peripheral T-cell Lymphoma Project score (IPTCLP), and the modified PIT (mPIT). [Read Article]

Project provides insight into T-cell lymphoma

Jen Smith Read Article
Published: 02/01/17

Federico-Massimo-TCLF2017-230.jpg
Massimo Federico, MD
Photo by Larry Young

The T-Cell Project has provided information that can enhance our understanding of T-cell lymphomas, according to a presentation at the 9th Annual T-cell Lymphoma Forum. The project is a prospective registry that includes data from T-cell lymphoma patients in 15 countries located in 5 different regions of the world.  The data showed that peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is the most common subtype of T-cell lymphoma . . . [Read Article]

Brentuximab vedotin bests standard of care in CTCL

Jen Smith Read Article
Published: 01/31/17

Kim-Youn-TCLF2017-230.jpg
Youn Kim, MD
Photo by Larry Young

The phase 3 ALCANZA trial is the first to convincingly demonstrate that a new systemic agent can be more effective than standard of care (SOC) options for cutaneous T-cell lymphoma (CTCL), according to a speaker at the 9th Annual T-cell Lymphoma Forum. The trial showed significant improvements in response, symptom burden, and progression-free survival (PFS) in patients with CD30-expressing CTCL who received brentuximab vedotin (BV) . . . [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}